tradingkey.logo

Haemonetics Corp

HAE
查看詳細走勢圖
79.910USD
-0.100-0.12%
交易中 美東報價延遲15分鐘
3.74B總市值
23.28本益比TTM

Haemonetics Corp

79.910
-0.100-0.12%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.12%

5天

+0.01%

1月

-0.89%

6月

+8.87%

今年開始到現在

+2.34%

1年

+3.23%

查看詳細走勢圖

TradingKey Haemonetics Corp股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Haemonetics Corp當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名26/206位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價85.91。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Haemonetics Corp評分

相關信息

行業排名
26 / 206
全市場排名
96 / 4562
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 11 分析師
買入
評級
85.909
目標均價
+3.24%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Haemonetics Corp亮點

亮點風險
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
業績高增長
公司營業收入穩步增長,連續3年增長16.44%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入1.36B美元
估值低估
公司最新PE估值23.30,處於3年歷史低位
機構減倉
最新機構持股54.60M股,環比減少8.66%
喬爾·格林布拉特持倉
明星投資者喬爾·格林布拉特持倉,最新持倉22.93K股
活躍度增加
近期活躍度增加,過去20天平均換手率1.27

Haemonetics Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Haemonetics Corp簡介

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
公司代碼HAE
公司Haemonetics Corp
CEOSimon (Christopher A)
網址https://www.haemonetics.com

常見問題

Haemonetics Corp(HAE)的當前股價是多少?

Haemonetics Corp(HAE)的當前股價是 79.910。

Haemonetics Corp 的股票代碼是什麼?

Haemonetics Corp的股票代碼是HAE。

Haemonetics Corp股票的52週最高點是多少?

Haemonetics Corp股票的52週最高點是87.320。

Haemonetics Corp股票的52週最低點是多少?

Haemonetics Corp股票的52週最低點是47.315。

Haemonetics Corp的市值是多少?

Haemonetics Corp的市值是3.74B。

Haemonetics Corp的淨利潤是多少?

Haemonetics Corp的淨利潤為167.68M。

現在Haemonetics Corp(HAE)的股票是買入、持有還是賣出?

根據分析師評級,Haemonetics Corp(HAE)的總體評級為買入,目標價格為85.909。

Haemonetics Corp(HAE)股票的每股收益(EPS TTM)是多少

Haemonetics Corp(HAE)股票的每股收益(EPS TTM)是3.433。
KeyAI